HC Wainwright Has Pessimistic View of VYGR FY2025 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Research analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Voyager Therapeutics in a research note issued to investors on Wednesday, November 12th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($1.98) per share for the year, down from their previous estimate of ($1.77). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q4 2025 earnings at ($0.41) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($1.49) EPS and FY2029 earnings at ($1.30) EPS.

A number of other equities research analysts have also commented on the company. Wedbush reiterated an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.12.

Voyager Therapeutics Stock Up 4.6%

Shares of NASDAQ:VYGR opened at $4.11 on Monday. The firm has a market cap of $228.52 million, a P/E ratio of -1.90 and a beta of 0.95. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $7.44. The business has a fifty day simple moving average of $4.54 and a 200 day simple moving average of $3.74.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.06. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. The company had revenue of $11.15 million for the quarter, compared to analyst estimates of $7.86 million.

Institutional Trading of Voyager Therapeutics

Several large investors have recently modified their holdings of the stock. Armistice Capital LLC increased its stake in shares of Voyager Therapeutics by 0.7% in the 1st quarter. Armistice Capital LLC now owns 5,436,000 shares of the company’s stock valued at $18,374,000 after acquiring an additional 40,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in Voyager Therapeutics by 1.3% in the third quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock worth $15,178,000 after purchasing an additional 40,147 shares during the period. Vestal Point Capital LP grew its holdings in Voyager Therapeutics by 1.6% in the first quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company’s stock worth $4,223,000 after purchasing an additional 19,418 shares during the period. Geode Capital Management LLC increased its stake in Voyager Therapeutics by 1.1% in the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after purchasing an additional 11,929 shares in the last quarter. Finally, Erste Asset Management GmbH raised its holdings in shares of Voyager Therapeutics by 5.5% during the first quarter. Erste Asset Management GmbH now owns 1,116,793 shares of the company’s stock valued at $3,826,000 after purchasing an additional 58,415 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Insiders Place Their Bets

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $4.78, for a total value of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares of the company’s stock, valued at approximately $591,926.52. The trade was a 5.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.